Acute myeloid leukaemia (AML) is a rapidly progressing cancer of the blood and bone marrow that originates from abnormal development of myeloid precursor cells. These immature cells normally develop into red blood cells, platelets, and certain types of white blood cells responsible for immune defence. In AML, genetic and molecular alterations cause these precursor cells to proliferate uncontrollably, preventing normal blood cell formation (Mayo Clinic, 2022; Cleveland Clinic, 2023).
As malignant myeloblasts accumulate within the bone marrow, they crowd out healthy blood-forming cells, leading to reduced oxygen transport, impaired clotting ability, and weakened immunity. This disruption of normal haematopoiesis results in widespread systemic effects that characterise the clinical presentation of AML (NATIONAL CANCER INSTITUTE, 2024; American Cancer Society, 2018). The disease often progresses quickly, requiring prompt diagnosis and medical intervention.
AML differs from lymphoid forms of leukaemia in that it affects myeloid lineage cells, which are responsible for producing granulocytes, monocytes, erythrocytes, and platelets. This distinction influences disease behaviour, treatment approaches, and prognosis. The rapid accumulation of immature myeloid cells also increases the risk of infection, bleeding, and organ dysfunction (Cleveland Clinic, 2023; Mayo Clinic, 2022).
From a biological perspective, AML is characterised by failure of normal cell maturation and dysregulation of programmed cell death. Abnormal cells continue dividing without differentiating into functional blood cells, leading to ineffective immune responses and metabolic instability (American Cancer Society, 2018). These cellular abnormalities may also infiltrate organs such as the liver, spleen, and central nervous system in advanced cases.
Functionally, acute myeloid leukaemia represents a breakdown in the body’s capacity to maintain balanced blood production and immune surveillance. Beyond physical illness, the condition imposes significant psychological, social, and emotional burdens due to its sudden onset, intensive treatment requirements, and uncertain outcomes (NATIONAL CANCER INSTITUTE, 2024; NHS, 2019). Recognising AML as both a biological and life-altering condition supports a comprehensive and compassionate approach to care.
Causes
The precise cause of acute myeloid leukaemia is not fully understood in most individuals. AML develops when genetic and molecular changes occur within immature myeloid cells in the bone marrow, causing them to multiply uncontrollably and lose their ability to mature into functional blood cells (Mayo Clinic, 2022; Cleveland Clinic, 2023). These abnormalities disrupt normal blood formation and lead to the accumulation of malignant myeloblasts.
Many of the genetic alterations associated with AML arise spontaneously and are not inherited. These changes may involve chromosomal translocations, gene mutations, or deletions that interfere with cellular growth regulation and programmed cell death (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024). As a result, abnormal cells evade natural control mechanisms and continue to proliferate.
Exposure to harmful environmental agents has been linked to increased AML risk in some cases. High levels of ionising radiation, industrial chemicals such as benzene, and toxic substances may damage DNA within bone marrow cells, promoting malignant transformation (Mayo Clinic, 2022; Cleveland Clinic, 2023). However, most patients do not recall any specific exposure, indicating that additional internal factors are involved.
Previous cancer treatment may also contribute to AML development. Chemotherapy and radiation therapy used for other malignancies can sometimes induce secondary genetic damage in bone marrow cells, leading to therapy-related AML years later (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024). This form of AML often presents with distinct biological features and may require specialised management.
Disorders affecting blood cell production may predispose individuals to AML. Conditions such as myelodysplastic syndromes and other bone marrow disorders can create an unstable cellular environment that increases the likelihood of malignant transformation (Cleveland Clinic, 2023; Mayo Clinic, 2022). These disorders reflect gradual deterioration of bone marrow regulation.
From a broader perspective, AML arises from complex interactions between genetic vulnerability and environmental influences. Rather than resulting from a single identifiable cause, the disease develops through progressive disruption of cellular control systems that normally maintain haematological balance (NATIONAL CANCER INSTITUTE, 2024; American Cancer Society, 2018). This multifactorial origin highlights the importance of continued research and early monitoring.
Signs and Symptoms
The signs and symptoms of acute myeloid leukaemia primarily arise from the replacement of healthy blood-forming cells in the bone marrow by abnormal myeloblasts. As normal blood cell production declines, individuals experience a range of systemic manifestations related to impaired immunity, reduced oxygen delivery, and altered clotting function (Mayo Clinic, 2022; Cleveland Clinic, 2023).
Persistent fatigue and weakness are among the most common early symptoms. These occur due to anaemia resulting from reduced red blood cell production. Individuals may experience breathlessness, pale skin, dizziness, and decreased physical endurance during routine activities (NHS, 2019; American Cancer Society, 2018). These symptoms often progress rapidly as the disease advances.
Increased susceptibility to infections is another hallmark feature of AML. The presence of immature and dysfunctional white blood cells weakens immune defence, making patients vulnerable to recurrent or severe infections. Frequent fevers, sore throat, prolonged illness, and delayed recovery are commonly reported (Mayo Clinic, 2022; NATIONAL CANCER INSTITUTE, 2024).
Bleeding and bruising tendencies develop as platelet levels decline. Patients may notice frequent nosebleeds, bleeding gums, prolonged bleeding from minor cuts, easy bruising, and the appearance of small red or purple spots on the skin known as petechiae (Cleveland Clinic, 2023; NHS, 2019). These symptoms reflect impaired clotting mechanisms.
Bone and joint pain may occur as abnormal cells accumulate within the bone marrow, increasing internal pressure. This discomfort is particularly noticeable in the long bones and may interfere with mobility and sleep (Mayo Clinic, 2022; American Cancer Society, 2018).
Enlargement of lymph nodes, liver, or spleen may develop as leukaemic cells spread beyond the bone marrow. This may lead to abdominal fullness, early satiety, weight loss, and discomfort (Cleveland Clinic, 2023; NATIONAL CANCER INSTITUTE, 2024). Swollen lymph nodes may be visible in the neck, armpits, or groin.
Systemic symptoms such as unexplained weight loss, night sweats, and persistent fever reflect the body’s inflammatory and metabolic response to malignancy (NHS, 2019; Mayo Clinic, 2022). These features often indicate disease progression.
In advanced cases, infiltration of the central nervous system may produce neurological symptoms such as headaches, visual disturbances, confusion, or seizures (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024). These manifestations require urgent medical attention.
Risk Factors
Several factors have been identified that may increase an individual’s likelihood of developing acute myeloid leukaemia, although many patients present without any clearly identifiable risk exposure. These risk factors are primarily associated with genetic vulnerability, environmental influences, and previous medical treatments (Mayo Clinic, 2022; Cleveland Clinic, 2023).
Age is one of the most significant risk factors for AML. The condition is more commonly diagnosed in older adults, with incidence increasing steadily after the age of 60. This age-related pattern reflects cumulative genetic damage and declining cellular repair mechanisms over time (NHS, 2019; American Cancer Society, 2018).
Exposure to ionising radiation represents a well-established risk factor. Individuals who have undergone radiation therapy for previous cancers or who have been exposed to high levels of environmental radiation may experience increased DNA damage within bone marrow cells, elevating leukaemia risk (Mayo Clinic, 2022; NATIONAL CANCER INSTITUTE, 2024).
Chemical exposure, particularly to benzene and related industrial solvents, has been associated with increased AML risk. Long-term occupational exposure in industries such as manufacturing, petroleum processing, and chemical production may contribute to bone marrow toxicity and genetic mutations (Cleveland Clinic, 2023; American Cancer Society, 2018).
Previous chemotherapy or radiotherapy for other malignancies may increase susceptibility to therapy-related AML. This secondary form of leukaemia may develop years after treatment due to cumulative genetic injury to haematopoietic cells (NATIONAL CANCER INSTITUTE, 2024; Mayo Clinic, 2022).
Pre-existing bone marrow disorders, including myelodysplastic syndromes and myeloproliferative disorders, significantly increase AML risk. These conditions reflect chronic instability in blood cell production and predispose individuals to malignant transformation (Cleveland Clinic, 2023; American Cancer Society, 2018).
Lifestyle factors may also influence susceptibility. Cigarette smoking has been linked to increased AML risk due to exposure to carcinogenic compounds that damage bone marrow DNA (Mayo Clinic, 2022; NHS, 2019). Smoking-related toxins may accumulate over time and impair cellular repair mechanisms.
Certain inherited genetic conditions may further elevate risk. Disorders affecting DNA repair and chromosomal stability increase vulnerability to malignant transformation, although such conditions are relatively rare (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024).
Complications
Acute myeloid leukaemia may give rise to multiple complications arising from both disease progression and disruption of normal blood cell production. As malignant myeloblasts replace healthy bone marrow cells, essential physiological functions related to immunity, oxygen transport, and clotting become progressively impaired (Mayo Clinic, 2022; Cleveland Clinic, 2023).
Severe infections represent one of the most serious complications of AML. Reduced production of functional white blood cells weakens immune defences, making patients highly susceptible to bacterial, viral, and fungal infections. Even minor infections may progress rapidly to life-threatening conditions such as sepsis if not promptly managed (NHS, 2019; NATIONAL CANCER INSTITUTE, 2024).
Anaemia-related complications are also common. Decreased red blood cell levels reduce oxygen delivery to tissues, leading to persistent fatigue, dizziness, cardiovascular strain, and reduced exercise tolerance. Prolonged anaemia may place additional stress on the heart and contribute to circulatory complications (Mayo Clinic, 2022; American Cancer Society, 2018).
Bleeding disorders develop as platelet counts decline. Thrombocytopenia increases vulnerability to spontaneous bleeding, gastrointestinal haemorrhage, and excessive bleeding following minor trauma. In severe cases, internal bleeding may occur within vital organs, including the brain (Cleveland Clinic, 2023; NHS, 2019).
Leukaemic infiltration of organs may result in structural and functional impairment. Accumulation of abnormal cells in the liver, spleen, and lymph nodes can disrupt metabolic regulation, immune coordination, and digestive processes. Organ enlargement may cause abdominal discomfort, nutritional deficiencies, and reduced physiological resilience (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024).
Central nervous system involvement may occur in advanced disease. Infiltration of leukaemic cells into the brain and spinal cord can lead to headaches, seizures, cognitive impairment, and visual disturbances. These neurological complications require specialised clinical management (Mayo Clinic, 2022; NATIONAL CANCER INSTITUTE, 2024).
Metabolic disturbances may arise during periods of rapid cell breakdown, particularly during treatment. Sudden release of cellular contents into the bloodstream can disrupt electrolyte balance and renal function, increasing cardiovascular strain (Cleveland Clinic, 2023; American Cancer Society, 2018).
Psychological and emotional complications frequently accompany physical illness. Prolonged treatment, uncertainty regarding prognosis, and social disruption may contribute to anxiety, depression, and emotional exhaustion in both patients and caregivers (NHS, 2019; American Cancer Society, 2018).
Prognosis
The prognosis of acute myeloid leukaemia varies according to age, genetic characteristics of leukaemic cells, response to treatment, and overall health status at diagnosis. Advances in medical research and treatment strategies have improved survival outcomes in many patients, particularly when the disease is diagnosed early and managed promptly (Mayo Clinic, 2022; Cleveland Clinic, 2023).
Younger individuals generally demonstrate more favourable outcomes compared to older adults. This difference reflects greater tolerance to intensive treatment and fewer coexisting medical conditions. Children and younger adults are more likely to achieve long-term remission, whereas prognosis tends to be more variable in elderly populations (American Cancer Society, 2018; NHS, 2019).
Genetic and molecular features of malignant cells play a central role in determining prognosis. Certain chromosomal abnormalities are associated with better treatment response, while others are linked to higher relapse risk. Modern diagnostic testing enables clinicians to classify patients into risk categories and tailor therapy accordingly (NATIONAL CANCER INSTITUTE, 2024; Mayo Clinic, 2022).
Early response to treatment remains one of the strongest predictors of long-term outcome. Patients who achieve rapid remission during initial therapy demonstrate improved survival compared to those with persistent disease activity (Cleveland Clinic, 2023; American Cancer Society, 2018). Continuous monitoring allows early detection of relapse and timely intervention.
Treatment-related complications may also influence prognosis. Some individuals experience lasting effects on organ function, immunity, or quality of life following intensive therapy. These long-term consequences require structured follow-up and supportive care (Mayo Clinic, 2022; NATIONAL CANCER INSTITUTE, 2024).
Psychological resilience and social support further contribute to recovery and wellbeing. Emotional stability, family involvement, and access to counselling services may enhance coping capacity, treatment adherence, and overall quality of life (NHS, 2019; American Cancer Society, 2018).
Types
Acute myeloid leukaemia is classified based on the type of immature myeloid cells involved and the genetic characteristics of malignant cells. These classifications help clinicians determine disease behaviour, select appropriate treatment strategies, and assess prognosis (Mayo Clinic, 2022; Cleveland Clinic, 2023).
Historically, AML was classified using the French–American–British (FAB) system, which categorised the disease based on cell appearance under microscopy. More recently, classification systems incorporate genetic, molecular, and immunological features to provide more precise risk stratification (American Cancer Society, 2018; NATIONAL CANCER INSTITUTE, 2024).
1. AML with Recurrent Genetic Abnormalities
This category includes AML subtypes characterised by specific chromosomal or genetic changes that influence disease behaviour and treatment response. Examples include translocations and gene rearrangements affecting cell maturation and proliferation (Mayo Clinic, 2022; American Cancer Society, 2018).
These genetic abnormalities are important predictors of prognosis. Some variants respond well to treatment, while others are associated with increased relapse risk. Identification of these changes allows clinicians to personalise therapy (NATIONAL CANCER INSTITUTE, 2024; Cleveland Clinic, 2023).
2. AML with Myelodysplasia-Related Changes
This type develops in individuals who previously had bone marrow disorders such as myelodysplastic syndromes. It reflects long-standing instability in blood cell production and is often associated with complex genetic abnormalities (American Cancer Society, 2018; Cleveland Clinic, 2023).
Patients with this subtype may have reduced treatment tolerance and a more variable prognosis, requiring careful monitoring and specialised management strategies (Mayo Clinic, 2022; NATIONAL CANCER INSTITUTE, 2024).
3. Therapy-Related AML
Therapy-related AML occurs as a complication of previous chemotherapy or radiation therapy administered for other cancers. Genetic damage induced by these treatments may lead to malignant transformation of bone marrow cells years later (Mayo Clinic, 2022; American Cancer Society, 2018).
This subtype is often biologically aggressive and may be associated with treatment resistance. Early recognition is essential for optimal management (Cleveland Clinic, 2023; NATIONAL CANCER INSTITUTE, 2024).
4. AML Not Otherwise Specified (AML-NOS)
AML-NOS includes cases that do not fit into specific genetic or secondary categories. These subtypes are primarily classified based on cellular morphology and immunophenotyping (American Cancer Society, 2018; Mayo Clinic, 2022).
Although grouped together, AML-NOS represents a heterogeneous population with varying clinical courses and treatment responses (Cleveland Clinic, 2023).
5. Acute Promyelocytic Leukaemia (APL)
Acute promyelocytic leukaemia is a distinct subtype of AML characterised by a specific chromosomal translocation that affects cell differentiation. It is associated with severe bleeding risk but responds well to targeted therapies when diagnosed early (Mayo Clinic, 2022; American Cancer Society, 2018).
With appropriate treatment, APL has one of the most favourable prognoses among AML subtypes (NATIONAL CANCER INSTITUTE, 2024; Cleveland Clinic, 2023).
Homeopathic Perspective
From a homeopathic perspective, acute myeloid leukaemia is viewed not merely as a disorder of abnormal blood cell proliferation, but as a manifestation of deeper systemic imbalance affecting the body’s vital force. Rather than focusing exclusively on malignant cellular changes, homeopathy seeks to understand the individual’s constitutional susceptibility, emotional disposition, metabolic tendencies, and long-term stress patterns that may contribute to disease expression.
Homeopathic philosophy considers chronic disturbances in digestion, immunity, emotional regulation, and detoxification capacity as potential contributors to long-term constitutional weakness. Repeated infections, prolonged medication exposure, suppressed inflammatory responses, and unresolved emotional stress are believed to gradually impair systemic resilience, creating conditions in which severe pathological changes may emerge.
Each individual with AML is assessed holistically, taking into account physical symptoms, energy levels, sleep patterns, appetite, emotional responses, temperature sensitivity, and stress coping mechanisms. Particular attention is given to patterns such as persistent fatigue, recurrent infections, unexplained weight changes, and emotional withdrawal, which may reflect deeper constitutional vulnerability.
Emotional factors are also considered significant. Chronic anxiety, suppressed grief, prolonged fear, and unresolved interpersonal stress may influence immune regulation through neuroendocrine pathways. From a homeopathic viewpoint, such emotional burdens may weaken physiological adaptability over time, reducing resistance to serious illness.
Supportive homeopathic care aims to strengthen overall vitality, improve adaptive capacity, and support emotional equilibrium alongside conventional medical treatment. Remedies are selected individually based on totality of symptoms rather than diagnostic labels. The intention is not to replace oncological care, but to complement it by addressing fatigue, appetite disturbances, sleep disruption, emotional distress, and treatment-related discomfort.
Homeopathic management also emphasises gentle stimulation of self-regulatory mechanisms, encouraging the body’s inherent capacity for balance and repair. This approach recognises that chronic illness affects multiple dimensions of health and therefore requires personalised, multidimensional support.
Importantly, ethical homeopathic practice acknowledges that AML is a life-threatening condition requiring specialised medical intervention. Homeopathy is positioned as a supportive modality that may enhance quality of life, emotional stability, and overall wellbeing when integrated responsibly within a comprehensive treatment plan.
Nutritional Perspective
From a nutritional perspective, acute myeloid leukaemia significantly affects the body’s metabolic demands, immune function, and capacity to maintain adequate nutrient balance. Individuals with AML often experience fatigue, reduced appetite, nausea, and weight loss, which may interfere with regular food intake and compromise nutritional status (Mayo Clinic, 2022; Cleveland Clinic, 2023). These challenges are further intensified during chemotherapy and other intensive treatments, which place additional stress on the digestive and immune systems.
Adequate nutrition plays a crucial role in supporting immune resilience, tissue repair, and energy production throughout treatment and recovery. Protein intake is particularly important for maintaining muscle mass, promoting wound healing, and supporting immune cell production (NHS, 2022). Insufficient protein consumption may contribute to weakness, delayed recovery, and increased vulnerability to infections.
Micronutrients such as iron, folate, vitamin B12, zinc, and vitamin C are essential for blood cell formation and immune regulation. However, treatment-related gastrointestinal disturbances may impair absorption of these nutrients, increasing the risk of deficiencies (NATIONAL CANCER INSTITUTE, 2024; Mayo Clinic, 2022). Balanced dietary patterns rich in fruits, vegetables, whole grains, and lean proteins help provide these essential nutrients in a bioavailable form.
Hydration is equally important in AML management. Adequate fluid intake supports kidney function, assists in metabolic waste elimination, and helps prevent dehydration associated with vomiting, diarrhoea, or fever (Cleveland Clinic, 2023). Maintaining proper hydration also supports circulatory stability and medication tolerance.
Food safety becomes a central nutritional concern for individuals with compromised immunity. Neutropenia, a common complication of AML and its treatment, increases susceptibility to infections. Therefore, strict food hygiene, avoidance of raw or undercooked foods, and proper storage practices are recommended to minimise infection risk (NHS, 2022; NATIONAL CANCER INSTITUTE, 2024).
Meal timing and portion control also influence nutritional tolerance. Small, frequent meals may be better tolerated than large portions, particularly in individuals experiencing nausea or early satiety (Mayo Clinic, 2022). Soft-textured, easily digestible foods may further reduce digestive discomfort and improve nutrient intake.
From a holistic standpoint, long-term nutritional stability contributes not only to physical strength but also to psychological resilience and treatment adherence. Consistent dietary support helps preserve energy levels, supports immune recovery, and enhances overall quality of life throughout the disease trajectory (Cleveland Clinic, 2023).
Psychological Perspective
A diagnosis of acute myeloid leukaemia represents a profound psychological challenge, often accompanied by intense emotional distress, uncertainty, and disruption of personal identity. Individuals diagnosed with AML commonly experience anxiety, fear, sadness, and feelings of helplessness as they confront the seriousness of the illness and the demands of intensive treatment (Mayo Clinic, 2022; Cleveland Clinic, 2023).
The sudden onset and aggressive nature of AML may contribute to psychological shock, particularly in individuals who were previously healthy. Concerns about prognosis, treatment side effects, financial burden, and family responsibilities frequently heighten emotional strain (NHS, 2022). This emotional burden may persist throughout diagnosis, treatment, and remission, requiring ongoing psychological adjustment.
Treatment-related factors further influence mental wellbeing. Prolonged hospitalisation, isolation due to infection risk, physical weakness, and visible bodily changes may lead to social withdrawal and reduced self-esteem (Cleveland Clinic, 2023). Fatigue and cognitive changes associated with chemotherapy may also affect concentration, memory, and emotional regulation, contributing to frustration and emotional exhaustion (Mayo Clinic, 2022).
Psychological stress has physiological implications that may influence immune function, sleep patterns, and appetite. Chronic anxiety and depression may interfere with treatment adherence and recovery processes, highlighting the interconnected relationship between emotional and physical health (NATIONAL CANCER INSTITUTE, 2024). Emotional distress may also manifest through somatic symptoms such as sleep disturbances, gastrointestinal discomfort, and persistent fatigue.
Support systems play a critical role in psychological resilience. Strong family involvement, peer support, and access to counselling services have been shown to improve coping capacity and emotional stability during cancer treatment (NHS, 2022). Open communication with healthcare providers further enhances patients’ sense of control and participation in decision-making.
Adaptive coping strategies, including mindfulness practices, relaxation techniques, journaling, and structured psychological therapy, may assist individuals in managing emotional distress. These approaches help regulate stress responses, foster emotional expression, and promote acceptance of changing life circumstances (Mayo Clinic, 2022).
From a holistic perspective, addressing psychological wellbeing is essential for comprehensive AML management. Emotional health influences motivation, self-care behaviours, and overall quality of life. Integrating psychological support within medical care frameworks supports long-term adjustment, strengthens resilience, and enhances therapeutic engagement (Cleveland Clinic, 2023).
Summary
Acute myeloid leukaemia is a serious and rapidly progressing blood disorder characterised by the abnormal proliferation of immature myeloid cells within the bone marrow and bloodstream. This uncontrolled growth interferes with normal blood cell production, leading to symptoms such as fatigue, infections, bleeding tendencies, and systemic weakness (Mayo Clinic, 2022; Cleveland Clinic, 2023). The condition reflects a complex interaction between genetic changes, environmental influences, immune dysregulation, and individual susceptibility (NATIONAL CANCER INSTITUTE, 2024; NHS, 2022).
Biomedical understanding highlights the importance of early diagnosis, intensive chemotherapy, and, in selected cases, stem cell transplantation in improving survival outcomes. However, AML also exerts profound effects on physical stamina, emotional wellbeing, nutritional status, and social functioning. Treatment-related complications and prolonged recovery periods further emphasise the need for comprehensive, multidisciplinary care (Mayo Clinic, 2022; Cleveland Clinic, 2023).
From a holistic perspective, effective AML management extends beyond disease eradication to include sustained support for immune resilience, metabolic balance, emotional stability, and quality of life. Nutritional optimisation supports tissue repair and immune recovery, while psychological interventions assist individuals in coping with uncertainty, fear, and treatment burden (NHS, 2022; NATIONAL CANCER INSTITUTE, 2024). Complementary approaches, when used responsibly alongside conventional care, may further enhance wellbeing and treatment tolerance.
The homeopathic viewpoint contributes a personalised understanding of constitutional vulnerability and emotional patterns, encouraging supportive care tailored to individual needs. When integrated ethically within medical frameworks, such approaches may assist in managing fatigue, stress, and overall vitality.
In conclusion, acute myeloid leukaemia represents not only a haematological emergency but also a multidimensional health challenge affecting physical, emotional, and social domains. Comprehensive management requires coordinated medical treatment, nutritional guidance, psychological support, and compassionate care. By adopting an integrated approach, healthcare systems can better address both survival outcomes and long-term wellbeing, enabling individuals with AML to navigate their illness with greater resilience, dignity, and support.
References
Mayo Clinic. (2022, September 21). Acute myelogenous leukaemia – Symptoms and causes. Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/acute-myelogenous-leukemia/symptoms-causes/syc-20369109
Cleveland Clinic. (2023, March 21). Acute myeloid leukaemia (AML): Causes, therapy, treatment & outlook. Cleveland Clinic. https://my.clevelandclinic.org/health/diseases/6212-acute-myeloid-leukemia-aml
National Cancer Institute. (2024, October 15). Adult acute myeloid leukaemia treatment. National Cancer Institute; Cancer.gov. https://www.cancer.gov/types/leukemia/patient/adult-aml-treatment-pdq
NHS. (2022). Overview – Acute myeloid leukaemia. NHS. https://www.nhs.uk/conditions/acute-myeloid-leukaemia/
American Cancer Society. (2018, August 21). What Is Acute Myeloid Leukaemia (AML)? | What Is AML? Www.cancer.org. https://www.cancer.org/cancer/types/acute-myeloid-leukemia/about/what-is-aml.html
Read more from the CMA’s Library of Conditions, Therapies and Remedies here
About the Author
Amrita Singh is a qualified Homoeopath, Psychologist, and Nutritionist with a strong multidisciplinary foundation in mind–body health. She holds an MSc in Psychology (UK) and an MSc in Food, Nutrition & Dietetics (India), alongside formal training in classical homoeopathy from the Central College of Homoeopathy, London. She is currently pursuing postgraduate studies with the Irish School of Homoeopathy.
A full member of the Complementary Medical Association (MCMA), Homoeopathy International (R. Hom. Int.), and the British Psychological Society (Graduate Member), and Balen’s insured, Amrita integrates emotional insight, nutritional balance, and gentle homoeopathic care in her clinical approach.
Formerly Head of Department at RMCH&RC, she now works with clients internationally, offering compassionate, holistic guidance that honours the interconnectedness of emotional wellbeing, physical health, and lifestyle patterns.
Contact & Credentials
Amrita Singh
Homoeopath, Psychologist & Nutritionist
Dip. CCH (England) | MSc Psychology (England) | MSc Food, Nutrition & Dietetics (India)
MCMA | R. Hom. Int. (Balen’s Insured) | GMBPsS
📧 [email protected]
🌐 https://amritasingh.co.uk/
📍 United Kingdom